References

  1. 1.Hassoun PM. Pulmonary arterial hypertension. N Engl J Med. 2021;385(25):2361-2376.
  2. 2.Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618-3731.
  3. 3.Hoeper MM, Humbert M, Souza R, et al. A global view of pulmonary hypertension. Lancet Respir Med. 2016;4(4):306-322.
  4. 4.Bousseau S, Sobrano Fais R, Gu S, et al. Pathophysiology and new advances in pulmonary hypertension. BMJ Med. 2023;2(1):e000137.
  5. 5.Virsinskaite R, Karia N, Kotecha T, et al. Pulmonary hypertension – the latest updates for physicians. Clin Med (Lond). 2023;23(5):449-454.
  6. 6.Thenappan T, Ormiston ML, Ryan JJ, et al. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ. 2018;360:j5492.
  7. 7.Raeisi-Giglou P, Lam L, Tamarappoo BK, et al. Evaluation of left ventricular diastolic function profile in patients with pulmonary hypertension due to heart failure with preserved ejection fraction. Clin Cardiol. 2017;40(6):356-363.
  8. 8.Weitsman T, Weisz G, Farkash R, et al. Pulmonary hypertension with left heart disease. Am J Med. 2017;130(11):1272-1279.
  9. 9.Kessler R, Faller M, Weitzenblum E, et al. “Natural history” of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med. 2001;164(2):219-224.
  10. 10.Blanco I, Tura-Ceide O, Peinado VI, et al. Updated perspectives on pulmonary hypertension in COPD. Int J Chron Obstruct Pulmon Dis. 2020;15:1315-1324.
  11. 11.Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006;129(3):746-752.
  12. 12.Nathan SD, Shlobin OA, Ahmad S, et al. Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respiration. 2008;76(3):288-294.
  13. 13.Shorr AF, Wainright JL, Cors CS, et al. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J. 2007;30(4):715-721.
  14. 14.Rose L, Prins KW, Archer SL, et al. Survival in pulmonary hypertension due to chronic lung disease: influence of low diffusion capacity of the lungs for carbon monoxide. J Heart Lung Transplant. 2019;38(2):145-155.
  15. 15.Leber L, Beaudet A, Muller A. Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review. Pulm Circ. 2021;11(1):2045894020977300.
  16. 16.Delcroix M, Torbicki A, Gopalan D, et al. ERS statement on chronic thromboembolic pulmonary hypertension. Eur Respir J. 2021;57(6):2002828.
  17. 17.Kramm T, Wilkens H, Fuge J, et al. Incidence and characteristics of chronic thromboembolic pulmonary hypertension in Germany. Clin Res Cardiol. 2018;107(7):548-553.
  18. 18.Barco S, Klok FA, Konstantinides SV, et al. Sex-specific differences in chronic thromboembolic pulmonary hypertension. Results from the European CTEPH registry. J Thromb Haemost. 2020;18(1):151-161.
  19. 19.Escribano-Subías P, Del Pozo R, Román-Broto A, et al.; REHAP Investigators. Management and outcomes in chronic thromboembolic pulmonary hypertension: from expert centers to a nationwide perspective. Int J Cardiol. 2016;203:938-944.
  20. 20.Highland KB, Crawford R, Classi P, et al. Development of the pulmonary hypertension functional classification self-report: a patient version adapted from the World Health Organization functional classification measure. Health Qual Life Outcomes. 2021;19(1):202.
  21. 21.Johnson S, Sommer N, Cox-Flaherty K, et al. Pulmonary hypertension: a contemporary review. Am J Respir Crit Care Med. 2023;208(5):528-548.
  22. 22.Tsujimoto Y, Kumasawa J, Shimizu S, et al. Doppler trans-thoracic echocardiography for detection of pulmonary hypertension in adults. Cochrane Database Syst Rev. 2022(5):CD012809.
  23. 23.Gall H, Yogeswaran A, Fuge J, et al. Validity of echocardiographic tricuspid regurgitation gradient to screen for new definition of pulmonary hypertension. EClinicalMedicine. 2021;34:100822.
  24. 24.Ahmed A, Ahmed S, Kempe D, et al. Evaluation of the European Society of Cardiology/European Respiratory Society derived three- and four-strata risk stratification models in pulmonary arterial hypertension: introducing an internet-based risk stratification calculator. Eur Heart J Open. 2023;3(2):oead012.
  25. 25.Villanueva J, Wade J, Torres A, et al. Sotatercept: the first FDA-approved activin A receptor IIa inhibitor used in the management of pulmonary arterial hypertension. Am J Cardiovasc Drugs. 2025;25(1):17-24.
  26. 26.Humbert M, McLaughlin V, Gibbs JSR, et al.; PULSAR Trial Investigators. Sotatercept for the treatment of pulmonary arterial hypertension. N Engl J Med. 2021;384(13):1204-1215.
  27. 27.Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e876-e894.
  28. 28.Klinger JR, Elliott CG, Levine DJ, et al. Therapy for pulmonary arterial hypertension in adults: update of the CHEST Guideline and Expert Panel Report. Chest. 2019;155(3):565-586.
  29. 29.Buys R, Avila A, Cornelissen VA. Exercise training improves physical fitness in patients with pulmonary arterial hypertension: a systematic review and meta-analysis of controlled trials. BMC Pulm Med. 2015;15:40.
  30. 30.Pandey A, Garg S, Khunger M, et al. Efficacy and safety of exercise training in chronic pulmonary hypertension: systematic review and meta-analysis. Circ Heart Fail. 2015;8(6):1032-1043.
  31. 31.Koudstaal T, Wapenaar M, van Ranst D, et al. The Effects of a 10-wk outpatient pulmonary rehabilitation program on exercise performance, muscle strength, soluble biomarkers, and quality of life in patients with pulmonary hypertension. J Cardiopulm Rehabil Prev. 2019;39(6):397-402.
  32. 32.Barret T, Degano B, Bouvaist H, et al. Routine rehabilitation as a treatment component for patients with pulmonary arterial or chronic thromboembolic pulmonary hypertensions. J Cardiopulm Rehabil Prev. 2023;43(5):354-360.
  33. 33.Morris NR, Kermeen FD, Jones AW, et al. Exercise-based rehabilitation programmes for pulmonary hypertension. Cochrane Database Syst Rev. 2023(3):CD011285.
  34. 34.Lan M, Wu S, Fernandes TM. Iron deficiency and pulmonary arterial hypertension. Nutr Clin Pract. 2022;37(5):1059-1073.
  35. 35.Rhodes CJ, Wharton J, Howard L, et al. Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target. Eur Respir J. 2011;38(6):1453-1460.
  36. 36.Zhang S, Li S, Gao L, et al. Effects of malnutrition on disease severity and adverse outcomes in idiopathic pulmonary arterial hypertension: a retrospective cohort study. Respir Res. 2024;25(1):292.
  37. 37.Huang Z, Duan A, Zhao Z, et al. Sleep-disordered breathing patterns and prognosis in pulmonary arterial hypertension: a cluster analysis of nocturnal cardiorespiratory signals. Sleep Med. 2024;113:61-69.
  38. 38.Adir Y, Humbert M, Chaouat A. Sleep-related breathing disorders and pulmonary hypertension. Eur Respir J. 2021;57(1):2002258.
  39. 39.Maligireddy A, Jabri A, Zghouzi M, et al. Maternal and fetal outcomes in pulmonary hypertension during pregnancy: a contemporary nationwide analysis. Am J Cardiol. 2024;221:113-119.
  40. 40.Nguyen AT, Curtis KM, Tepper NK, et al. US medical eligibility criteria for contraceptive use, 2024. MMWR Recomm Rep. 2024;73(4):1-126.
  41. 41.Barua RS, Rigotti NA, Benowitz NL, et al. 2018 ACC expert consensus decision pathway on tobacco cessation treatment: a report of the American College of Cardiology Task Force on clinical expert consensus documents. J Am Coll Cardiol. 2018;72(25):3332-3365.
  42. 42.Tønnesen P, Carrozzi L, Fagerström KO, et al. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur Respir J. 2007;29(2):390-417.
  43. 43.Sitbon O, Channick R, Chin KM, et al.; GRIPHON Investigators. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522-2533.
  44. 44.Feenstra J, Hopkins P, Trotter M, et al. Effectiveness of epoprostenol in the management of pulmonary arterial hypertension: findings of an Australian retrospective chart review. Intern Med J. 2020;50(11):1377-1384.
  45. 45.Barst RJ, Rubin LJ, Long WA, et al.; Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334(5):296-301.
  46. 46.Galiè N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801889.
  47. 47.Frantz RP. Group 2 pulmonary hypertension: from diagnosis to treatment. Curr Opin Pulm Med. 2023;29(5):391-398.
  48. 48.Wiener RS, Ouellette DR, Diamond E, et al. An official American Thoracic Society/American College of Chest Physicians policy statement: the Choosing Wisely top five list in adult pulmonary medicine. Chest. 2014;145(6):1383-1391.
  1. 1.Mazzone PJ, Lam L. Evaluating the patient with a pulmonary nodule: a review. JAMA. 2022;327(3):264-273.
  2. 2.Gould MK, Tang T, Liu ILA, et al. Recent trends in the identification of incidental pulmonary nodules. Am J Respir Crit Care Med. 2015;192(10):1208-1214.
  3. 3.McWilliams A, Tammemagi MC, Mayo JR, et al. Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med. 2013;369(10):910-919.
  4. 4.Ost DE, Jim Yeung SC, Tanoue LT, et al. Clinical and organizational factors in the initial evaluation of patients with lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 suppl):e121S-e141S.
  5. 5.Zhuang W, Xu H, Wu J, et al. Patient-reported respiratory symptoms and relevant factors in patients with pulmonary nodules. J Thorac Dis. 2024;16(7):4097-4105.
  6. 6.Borczuk AC. Neoplastic and nonneoplastic benign mass lesions of the lung. Arch Pathol Lab Med. 2012;136(10):1227-1233.
  7. 7.Bai C, Choi CM, Chu CM, et al. Evaluation of pulmonary nodules: clinical practice consensus guidelines for Asia. Chest. 2016;150(4):877-893.
  8. 8.Copp DH, Godwin JD, Kirby KA, et al. Clinical and radiologic factors associated with pulmonary nodule etiology in organ transplant recipients. Am J Transplant. 2006;6(11):2759-2764.
  9. 9.Li X, Jin F, Zhou T, et al. Diagnostic accuracy of CT-guided percutaneous pulmonary biopsy for distinguishing benign and malignant solitary pulmonary nodules. Altern Ther Health Med. 2023;29(8):918-923.
  10. 10.Reid M, Choi HK, Han X, et al. Development of a risk prediction model to estimate the probability of malignancy in pulmonary nodules being considered for biopsy. Chest. 2019;156(2):367-375.
  11. 11.Vachani A, Zheng C, Amy Liu IL, et al. The probability of lung cancer in patients with incidentally detected pulmonary nodules: clinical characteristics and accuracy of prediction models. Chest. 2022;161(2):562-571.
  12. 12.Alberg AJ, Brock MV, Ford JG, et al. Epidemiology of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 suppl):e1S-e29S.
  13. 13.Jaklitsch MT, Jacobson FL, Austin JHM, et al. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg. 2012;144(1):33-38.
  14. 14.Cronin KA, Scott S, Firth AU, et al. Annual report to the nation on the status of cancer, part 1: national cancer statistics. Cancer. 2022;128(24):4251-4284.
  15. 15.Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33.
  16. 16.Krist AH, Davidson KW, Mangione CM, et al. Screening for lung cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325(10):962-970.
  17. 17.Howlader N, Forjaz G, Mooradian MJ, et al. The effect of advances in lung-cancer treatment on population mortality. N Engl J Med. 2020;383(7):640-649.
  18. 18.Goddard KAB, Feuer EJ, Mandelblatt JS, et al. Estimation of cancer deaths averted from prevention, screening, and treatment efforts, 1975-2020. JAMA Oncol. 2025;11(2):162-167.
  19. 19.Mazzone PJ, Silvestri GA, Souter LH, et al. Screening for lung cancer: CHEST guideline and expert panel report. Chest. 2021;160(5):e427-e494.
  20. 20.Jonas DE, Reuland DS, Reddy SM, et al. Screening for lung cancer with low-dose computed tomography: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2021;325(10):971-987.
  21. 21.Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012;307(22):2418-2429.
  22. 22.Wood DE, Kazerooni EA, Baum SL, et al. Lung cancer screening, version 3.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16(4):412-441.
  23. 23.Aberle DR, Adams AM, Berg CD, et al.; National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409.
  24. 24.Walter JE, Heuvelmans MA, Yousaf-Khan U, et al. New subsolid pulmonary nodules in lung cancer screening: The NELSON Trial. J Thorac Oncol. 2018;13(9):1410-1414.
  25. 25.Kovalchik SA, Tammemagi M, Berg CD, et al. Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med. 2013;369(3):245-254.
  26. 26.Aberle DR, Abtin F, Brown K. Computed tomography screening for lung cancer: has it finally arrived? Implications of the national lung screening trial. J Clin Oncol. 2013;31(8):1002-1008.
  27. 27.Wolf AMD, Oeffinger KC, Shih TYC, et al. Screening for lung cancer: 2023 guideline update from the American Cancer Society. CA Cancer J Clin. 2024;74(1):50-81.
  28. 28.Zhao H, Xu Y, Huo J, et al. Updated analysis of complication rates associated with invasive diagnostic procedures after lung cancer screening. JAMA Netw Open. 2020;3(12):e2029874.
  29. 29.Gareen IF, Duan F, Greco EM, et al. Impact of lung cancer screening results on participant health-related quality of life and state anxiety in the National Lung Screening Trial. Cancer. 2014;120(21):3401-3409.
  30. 30.Rampinelli C, De Marco P, Origgi D, et al. Exposure to low dose computed tomography for lung cancer screening and risk of cancer: secondary analysis of trial data and risk-benefit analysis. BMJ. 2017;356:j347.
  31. 31.Wulaningsih W, Villamaria C, Akram A, et al. Deep learning models for predicting malignancy risk in CT-detected pulmonary nodules: a systematic review and meta-analysis. Lung. 2024;202(5):625-636.
  32. 32.Susam S, Çinkooğlu A, Ceylan KC, et al. Comparison of Brock University, Mayo Clinic and Herder models for pretest probability of cancer in solid pulmonary nodules. Clin Respir J. 2022;16(11):740-749.
  33. 33.González Maldonado S, Delorme S, Hüsing A, et al. Evaluation of prediction models for identifying malignancy in pulmonary nodules detected via low-dose computed tomography. JAMA Netw Open. 2020;3(2):e1921221.
  34. 34.Al-Ameri A, Malhotra P, Thygesen H, et al. Risk of malignancy in pulmonary nodules: a validation study of four prediction models. Lung Cancer. 2015;89(1):27-30.
  35. 35.Jhala K, Byrne SC, Hammer MM. Interpreting lung cancer screening CTs: practical approach to lung cancer screening and application of Lung-RADS. Clin Chest Med. 2024;45(2):279-293.
  36. 36.Christensen J, Prosper AE, Wu CC, et al. ACR Lung-RADS v2022: assessment categories and management recommendations. J Am Coll Radiol. 2024;21(3):473-488.
  37. 37.Massion PP, Antic S, Ather S, et al. Assessing the accuracy of a deep learning method to risk stratify indeterminate pulmonary nodules. Am J Respir Crit Care Med. 2020;202(2):241-249.
  38. 38.Wang C, Shao J, Xu X, et al. DeepLN: a multi-task AI tool to predict the imaging characteristics, malignancy and pathological subtypes in CT-detected pulmonary nodules. Front Oncol. 2022;12:683792.
  39. 39.MacMahon H, Naidich DP, Goo JM, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017. Radiology. 2017;284(1):228-243.
  40. 40.Farjah F, Monsell SE, Smith-Bindman R, et al. Fleischner Society guideline recommendations for incidentally detected pulmonary nodules and the probability of lung cancer. J Am Coll Radiol. 2022;19(11):1226-1235.
  41. 41.Gould MK, Donington J, Lynch WR, et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd, ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 suppl):e93S-e120S.
  42. 42.American College of Radiology. Lung-RADS. Lung CT Reporting and Data System. https://www.acr.org/Clinical-Resources/Clinical-Tools-and-Reference/Reporting-and-Data-Systems/Lung-RADS
  43. 43.Ma Q, Huang CX, He JW, et al. Oral microbiota as a biomarker for predicting the risk of malignancy in indeterminate pulmonary nodules: a prospective multicenter study. Int J Surg. 2025;111(2):2055-2071.
  44. 44.Vogtmann E, Hua X, Yu G, et al. The oral microbiome and lung cancer risk: an analysis of 3 prospective cohort studies. J Natl Cancer Inst. 2022;114(11):1501-1510.
  45. 45.Deng CJ, Dai FQ, Qian K, et al. Clinical updates of approaches for biopsy of pulmonary lesions based on systematic review. BMC Pulm Med. 2018;18(1):146.
  46. 46.Constantinescu A, Stoicescu ER, Iacob R, et al. CT-guided transthoracic core-needle biopsy of pulmonary nodules: current practices, efficacy, and safety considerations. J Clin Med. 2024;13(23):7330.
  47. 47.Martin MD, Henry TS, Berry MF, et al.; Expert Panel on Thoracic Imaging. ACR Appropriateness Criteria® incidentally detected indeterminate pulmonary nodule. J Am Coll Radiol. 2023;20(11 suppl):S455-S470.
  48. 48.Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 suppl):e142S-e165S.
  49. 49.Yang W, Sun W, Li Q, et al. Diagnostic accuracy of CT-guided transthoracic needle biopsy for solitary pulmonary nodules. PLoS One. 2015;10(6):e0131373.
  1. 1.Mokhlesi B, Masa JF, Brozek JL, et al. Evaluation and management of obesity hypoventilation syndrome: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2019;200(3):e6-e24.
  2. 2.Randerath W, Verbraecken J, Andreas S, et al. Definition, discrimination, diagnosis and treatment of central breathing disturbances during sleep. Eur Respir J. 2017;49(1):1600959.
  3. 3.World Health Organization. Obesity and overweight. May 7, 2025. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
  4. 4.Ward ZJ, Bleich SN, Cradock AL, et al. Projected US state-level prevalence of adult obesity and severe obesity. N Engl J Med. 2019;381(25):2440-2450.
  5. 5.National Center for Chronic Disease Prevention and Health Promotion. Adult BMI categories. https://www.cdc.gov/bmi/adult-calculator/bmi-categories.html
  6. 6.Nowbar S, Burkart KM, Gonzales R, et al. Obesity-associated hypoventilation in hospitalized patients: prevalence, effects, and outcome. Am J Med. 2004;116(1):1-7.
  7. 7.Mokhlesi B. Obesity hypoventilation syndrome: a state-of-the-art review. Respir Care. 2010;55(10):1347-1362.
  8. 8.International Classification of Sleep Disorders – Text Revision. 3rd ed. American Academy of Sleep Medicine; 2023.
  9. 9.Quint JK, Ward L, Davison AG. Previously undiagnosed obesity hypoventilation syndrome. Thorax. 2007;62(5):462-463.
  10. 10.Orozco González BN, Rodriguez Plascencia N, Palma Zapata JA, et al. Obesity hypoventilation syndrome, literature review. Sleep Adv. 2024;5(1):zpae033.
  11. 11.Berg G, Delaive K, Manfreda J, et al. The use of health-care resources in obesity-hypoventilation syndrome. Chest. 2001;120(2):377-383.
  12. 12.Pillar G, Shehadeh N. Abdominal fat and sleep apnea: the chicken or the egg? Diabetes Care. 2008;31(7 suppl 2):S303-S309.
  13. 13.Kaw R, Dupuy-McCauley K, Wong J. Screening and perioperative management of obesity hypoventilation syndrome. J Clin Med. 2024;13(17):5000.
  14. 14.Balachandran JS, Masa JF, Mokhlesi B. Obesity hypoventilation syndrome: epidemiology and diagnosis. Sleep Med Clin. 2014;9(3):341-347.
  15. 15.Kakazu MT, Soghier I, Afshar M, et al. Weight loss interventions as treatment of obesity hypoventilation syndrome: a systematic review. Ann Am Thorac Soc. 2020;17(4):492-502.
  16. 16.Wearn J, Akpa B, Mokhlesi B. Adherence to positive airway pressure therapy in obesity hypoventilation syndrome. Sleep Med Clin. 2021;16(1):43-59.
  17. 17.Mandal S, Suh ES, Harding R, et al. Nutrition and exercise rehabilitation in obesity hypoventilation syndrome (NERO): a pilot randomised controlled trial. Thorax. 2018;73(1):62-69.
  18. 18.Mokhlesi B, Kryger MH, Grunstein RR. Assessment and management of patients with obesity hypoventilation syndrome. Proc Am Thorac Soc. 2008;5(2):218-225.
  19. 19.Nauck MA, Wollschläger D, Werner J, et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia. 1996;39(12):1546-1553.
  20. 20.Ghusn W, De la Rosa A, Sacoto D, et al. Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity. JAMA Netw Open. 2022;5(9):e2231982.
  21. 21.Kent D, Stanley J, Aurora RN, et al. Referral of adults with obstructive sleep apnea for surgical consultation: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17(12):2499-2505.
  22. 22.Mirabile VS, Shebl E, Sankari A, et al. Respiratory failure in adults. In: StatPearls. June 11, 2023.https://www.ncbi.nlm.nih.gov/books/NBK526127/
  23. 23.Afshar M, Brozek JL, Soghier I, et al. The role of positive airway pressure therapy in adults with obesity hypoventilation syndrome: a systematic review and meta-analysis. Ann Am Thorac Soc. 2020;17(3):344-360.
  24. 24.Wang Z, Wilson M, Dobler CC, et al. Noninvasive Positive Pressure Ventilation in the Home. Technology Assessment Program. Agency for Healthcare Research and Quality; 2019:1-79.
  25. 25.Berry RB, Parish JM, Hartse KM. The use of auto-titrating continuous positive airway pressure for treatment of adult obstructive sleep apnea. An American Academy of Sleep Medicine review. Sleep. 2002;25(2):148-173.
  26. 26.Xu J, Wei Z, Li W, et al. Effect of different modes of positive airway pressure treatment on obesity hypoventilation syndrome: a systematic review and network meta-analysis. Sleep Med. 2022;91:51-58.
  27. 27.Soghier I, Brożek JL, Afshar M, et al. Noninvasive ventilation versus CPAP as initial treatment of obesity hypoventilation syndrome. Ann Am Thorac Soc. 2019;16(10):1295-1303.
  28. 28.Mokhlesi B, Masa JF, Afshar M, et al. The effect of hospital discharge with empiric noninvasive ventilation on mortality in hospitalized patients with obesity hypoventilation syndrome: an individual patient data meta-analysis. Ann Am Thorac Soc. 2020;17(5):627-637.
  29. 29.Murphy PB, Patout M, Arbane G, et al. Cost-effectiveness of outpatient versus inpatient non-invasive ventilation setup in obesity hypoventilation syndrome: the OPIP trial. Thorax. 2023;78(1):24-31.
  30. 30.Kampelmacher MJ. Moving from inpatient to outpatient or home initiation of non-invasive home mechanical ventilation. J Clin Med. 2023;12(8):2981.
  31. 31.D’Cruz RF, Kaltsakas G, Suh ES, et al. Quality of life in patients with chronic respiratory failure on home mechanical ventilation. Eur Respir Rev. 2023;32(168):220237.
  32. 32.Brown LK. Targeting hypercapnia in chronic lung disease and obesity hypoventilation: benefits and challenges. Sleep Med Clin. 2024;19(2):357-369.
  1. 1.Feller-Kopman D, Light R. Pleural disease. N Engl J Med. 2018;378(8):740-751.
  2. 2.Light RW. Clinical practice: pleural effusion. N Engl J Med. 2002;346(25):1971-1977.
  3. 3.Light RW. Pleural effusions. Med Clin North Am. 2011;95(6):1055-1070.
  4. 4.Mummadi SR, Stoller JK, Lopez R, et al. Epidemiology of adult pleural disease in the United States. Chest. 2021;160(4):1534-1551.
  5. 5.Shen-Wagner J, Gamble C, MacGilvray P. Pleural effusion: diagnostic approach in adults. Am Fam Physician. 2023;108(5):464-475.
  6. 6.Wong CL, Holroyd-Leduc J, Straus SE. Does this patient have a pleural effusion? JAMA. 2009;301(3):309-317.
  7. 7.Korczyński P, Górska K, Konopka D, et al. Significance of congestive heart failure as a cause of pleural effusion: pilot data from a large multidisciplinary teaching hospital. Cardiol J. 2020;27(3):254-261.
  8. 8.Marel M, Stastny B, Melínová L, et al. Diagnosis of pleural effusions: experience with clinical studies, 1986 to 1990. Chest. 1995;107(6):1598-1603.
  9. 9.Bintcliffe OJ, Hooper CE, Rider IJ, et al. Unilateral pleural effusions with more than one apparent etiology: a prospective observational study. Ann Am Thorac Soc. 2016;13(7):1050-1056.
  10. 10.Eibenberger KL, Dock WI, Ammann ME, et al. Quantification of pleural effusions: sonography versus radiography. Radiology. 1994;191(3):681-684.
  11. 11.Balik M, Plasil P, Waldauf P, et al. Ultrasound estimation of volume of pleural fluid in mechanically ventilated patients. Intensive Care Med. 2006;32(2):318.
  12. 12.Shen KR, Bribriesco A, Crabtree T, et al. The American Association for Thoracic Surgery consensus guidelines for the management of empyema. J Thorac Cardiovasc Surg. 2017;153(6):e129-e146.
  13. 13.Soni NJ, Franco R, Velez MI, et al. Ultrasound in the diagnosis and management of pleural effusions. J Hosp Med. 2015;10(12):811-816.
  14. 14.Shkolnik B, Judson MA, Austin A, et al. Diagnostic accuracy of thoracic ultrasonography to differentiate transudative from exudative pleural effusion. Chest. 2020;158(2):692-697.
  15. 15.Qureshi NR, Rahman NM, Gleeson FV. Thoracic ultrasound in the diagnosis of malignant pleural effusion. Thorax. 2009;64(2):139-143.
  16. 16.Svigals PZ, Chopra A, Ravenel JG, et al. The accuracy of pleural ultrasonography in diagnosing complicated parapneumonic pleural effusions. Thorax. 2017;72(1):94-95.
  17. 17.Staub LJ, Biscaro RRM, Kaszubowski E, et al. Chest ultrasonography for the emergency diagnosis of traumatic pneumothorax and haemothorax: a systematic review and meta-analysis. Injury. 2018;49(3):457-466.
  18. 18.Rahimi-Movaghar V, Yousefifard M, Ghelichkhani P, et al. Application of ultrasonography and radiography in detection of hemothorax; a systematic review and meta-analysis. Emergency (Tehran). 2016;4(3):116-126.
  19. 19.Porcel JM. Nonmalignant pleural effusions. Semin Respir Crit Care Med. 2022;43(4):570-582.
  20. 20.Asciak R, Bedawi EO, Bhatnagar R, et al. British Thoracic Society clinical statement on pleural procedures. Thorax. 2023;78(suppl 3):s43-s68.
  21. 21.Diacon AH, Brutsche MH, Solèr M. Accuracy of pleural puncture sites: a prospective comparison of clinical examination with ultrasound. Chest. 2003;123(2):436-441.
  22. 22.Gordon CE, Feller-Kopman D, Balk EM, et al. Pneumothorax following thoracentesis: a systematic review and meta-analysis. Arch Intern Med. 2010;170(4):332-339.
  23. 23.Sundaralingam A, Bedawi EO, Harriss EK, et al. The frequency, risk factors, and management of complications from pleural procedures. Chest. 2022;161(5):1407-1425.
  24. 24.Wilcox ME, Chong CAKY, Stanbrook MB, et al. Does this patient have an exudative pleural effusion? The rational clinical examination systematic review. JAMA. 2014;311(23):2422-2431.
  25. 25.Roberts ME, Rahman NM, Maskell NA, et al. British Thoracic Society guideline for pleural disease. Thorax. 2023;78(11):1143-1156.
  26. 26.Light RW, Macgregor MI, Luchsinger PC, et al. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med. 1972;77(4):507-513.
  27. 27.Porcel JM, Light RW. Diagnostic approach to pleural effusion in adults. Am Fam Physician. 2006;73(7):1211-1220.
  28. 28.Han ZJ, Wu XD, Cheng JJ, et al. Diagnostic accuracy of natriuretic peptides for heart failure in patients with pleural effusion: a systematic review and updated meta-analysis. PLoS One. 2015;10(8):e0134376.
  29. 29.Porcel JM, Martínez-Alonso M, Cao G, et al. Biomarkers of heart failure in pleural fluid. Chest. 2009;136(3):671-677.
  30. 30.Lindenmann J, Matzi V, Neuboeck N, et al. Management of esophageal perforation in 120 consecutive patients: clinical impact of a structured treatment algorithm. J Gastrointest Surg. 2013;17(6):1036-1043.
  31. 31.Mohan G, Bhide P, Agrawal A, et al. A practical approach to pseudoexudative pleural effusions. Respir Med. 2023;214:107279.
  32. 32.Zhou Q, Ye ZJ, Su Y, et al. Diagnostic value of N-terminal pro-brain natriuretic peptide for pleural effusion due to heart failure: a meta-analysis. Heart. 2010;96(15):1207-1211.
  33. 33.Peterman TA, Speicher CE. Evaluating pleural effusions: a two-stage laboratory approach. JAMA. 1984;252(8):1051-1053.
  34. 34.Romero-Candeira S, Fernández C, Martín C, et al. Influence of diuretics on the concentration of proteins and other components of pleural transudates in patients with heart failure. Am J Med. 2001;110(9):681-686.
  35. 35.Burgess LJ, Maritz FJ, Taljaard JJ. Comparative analysis of the biochemical parameters used to distinguish between pleural transudates and exudates. Chest. 1995;107(6):1604-1609.
  36. 36.Light RW, Erozan YS, Ball WC. Cells in pleural fluid: their value in differential diagnosis. Arch Intern Med. 1973;132(6):854-860.
  37. 37.Low SW, Boyle T, Shojaee S. Management of recurrent transudative effusions in congestive heart failure and hepatic hydrothorax. Clin Chest Med. 2025;46(2):261-269.
  38. 38.Kinasewitz GT, Keddissi JI. Hepatic hydrothorax. Curr Opin Pulm Med. 2003;9(4):261-265.
  39. 39.Cerfolio RJ, Bryant AS. Efficacy of video-assisted thoracoscopic surgery with talc pleurodesis for porous diaphragm syndrome in patients with refractory hepatic hydrothorax. Ann Thorac Surg. 2006;82(2):457-459.
  40. 40.Stein PD, Henry JW. Clinical characteristics of patients with acute pulmonary embolism stratified according to their presenting syndromes. Chest. 1997;112(4):974-979.
  41. 41.Bynum LJ, Wilson JE. Radiographic features of pleural effusions in pulmonary embolism. Am Rev Respir Dis. 1978;117(5):829-834.
  42. 42.Yan DT, Heng RGK, Ng HJ. Massive spontaneous haemothorax after rivaroxaban therapy for acute pulmonary embolism. Eur J Case Rep Intern Med. 2019;6(10):001236.
  43. 43.Michel L, Grillo HC, Malt RA. Operative and nonoperative management of esophageal perforations. Ann Surg. 1981;194(1):57-63.
  44. 44.Abbott OA, Mansour KA, Logan WD, et al. Atraumatic so-called “spontaneous” rupture of the esophagus: a review of 47 personal cases with comments on a new method of surgical therapy. J Thorac Cardiovasc Surg. 1970;59(1):67-83.
  45. 45.Raghu MG, Wig JD, Kochhar R, et al. Lung complications in acute pancreatitis. JOP. 2007;8(2):177-185.
  46. 46.Iyer H, Elhence A, Mittal S, et al. Pulmonary complications of acute pancreatitis. Expert Rev Respir Med. 2020;14(2):209-217.
  47. 47.Light RW, Rogers JT, Moyers JP, et al. Prevalence and clinical course of pleural effusions at 30 days after coronary artery and cardiac surgery. Am J Respir Crit Care Med. 2002;166(12 pt 1):1567-1571.
  48. 48.Sadikot RT, Rogers JT, Cheng DS, et al. Pleural fluid characteristics of patients with symptomatic pleural effusion after coronary artery bypass graft surgery. Arch Intern Med. 2000;160(17):2665-2668.
  49. 49.Feller-Kopman DJ, Reddy CB, DeCamp MM, et al. Management of malignant pleural effusions: an official ATS/STS/STR clinical practice guideline. Am J Respir Crit Care Med. 2018;198(7):839-849.

Current edition

Hepatitis Overview

Hepatitis Overview

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.